| human | Q5 |
| P6178 | Dimensions author ID | 01222331552.43 |
| P12541 | Ludzie Nauki ID (new) | dvLycpQ1cuc |
| P496 | ORCID iD | 0000-0001-9999-0267 |
| P3124 | Polish scientist ID | 97496 |
| P512 | academic degree | habilitation | Q308678 |
| doctorate | Q849697 | ||
| scientific professorship degree | Q55695329 | ||
| P185 | doctoral student | Agata Sebastian | Q88929531 |
| Marta Madej | Q89485793 | ||
| P69 | educated at | Wrocław Medical University | Q1916589 |
| P108 | employer | Wrocław Medical University | Q1916589 |
| P734 | family name | Wiland | Q37499262 |
| Wiland | Q37499262 | ||
| Wiland | Q37499262 | ||
| P735 | given name | Piotr | Q15897269 |
| Piotr | Q15897269 | ||
| P106 | occupation | physician | Q39631 |
| researcher | Q1650915 | ||
| rheumatologist | Q5997943 | ||
| P21 | sex or gender | male | Q6581097 |
| Q33731743 | A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis |
| Q36516361 | Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. |
| Q42747770 | Active psoriatic arthritis during pregnancy: challenges and limitations of pharmacotherapy |
| Q48900594 | Activity of JAK/STAT and NF-kB in patients with axial spondyloarthritis. |
| Q55381625 | Addendum: Iwaszko et al., Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes 2018, 9, 64. |
| Q37681485 | Alterations in both the activatory and inhibitory potential of peripheral blood CD4+ T cells in rheumatoid arthritis patients correlate with disease progression |
| Q85774447 | Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis |
| Q85618243 | Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus |
| Q51097375 | Antibodies against monomeric C-reactive protein - a promising biomarker of lupus nephritis? |
| Q36065421 | Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. |
| Q89983758 | Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis |
| Q86554778 | Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis |
| Q58594045 | Autoantibody and metalloproteinase activity in early arthritis |
| Q100474382 | Autoimmune congenital heart block and primary Sjögren's syndrome: characterisation and outcomes of 49 cases |
| Q38212141 | Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries |
| Q58779818 | Biosimilar switching - current state of knowledge |
| Q114905009 | Brainstem auditory evoked potentials in patients with primary Sjögren’s syndrome without central nervous system involvement |
| Q91834941 | CD4+CD28null T cells are expanded in moderately active systemic lupus erythematosus and secrete pro-inflammatory interferon gamma, depending on the Disease Activity Index |
| Q47688740 | Chest HRCT findings in patients with primary Sjögren's syndrome |
| Q92026302 | Classification criteria for secondary Sjögren's syndrome. Current state of knowledge |
| Q89378846 | Cognitive impairment, event-related potentials and immunological status in patients with systemic lupus erythematosus |
| Q91934214 | Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis |
| Q64987356 | Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. |
| Q115194456 | Consensus Statement on the use of cyclosporin A in patients with severe keratitis in dry eye syndrome in ophthalmology, rheumatology and hematology* |
| Q39608151 | Cytokine profiles in axial spondyloarthritis |
| Q40446841 | Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. |
| Q87402220 | Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis |
| Q43233004 | Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy |
| Q117119023 | Do KIR genes impact the susceptibility to ankylosing spondylitis in Polish patients? |
| Q33701536 | Does the KIR2DS5 gene protect from some human diseases? |
| Q89919542 | Dr. Wiland, et al, reply |
| Q91611270 | Dysregulated interferon-γ and interleukin-2 synthesis in peripheral blood T cells in quiescent systemic lupus erythematosus is dependent on the affected T-cell receptor ζ chain expression |
| Q39043111 | EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis |
| Q38375767 | Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. |
| Q37616966 | Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study |
| Q31085610 | Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study |
| Q92655671 | Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial |
| Q38375620 | Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial. |
| Q102369992 | Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial |
| Q92232344 | Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome |
| Q36085041 | Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group |
| Q37031217 | Erythema nodosum - presentation of three cases |
| Q26740999 | Erythema nodosum - review of the literature |
| Q36771435 | Etanercept treatment in juvenile idiopathic arthritis: the Polish registry |
| Q93090532 | Factors associated with quality of life in systemic sclerosis: a cross-sectional study |
| Q74479814 | High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment |
| Q91196740 | How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project) |
| Q55283251 | How to Distinguish Patients with pSS among Individuals with Dryness without Invasive Diagnostic Studies. |
| Q35598656 | IL-17A, IL-17F and IL-23R Gene Polymorphisms in Polish Patients with Rheumatoid Arthritis |
| Q90395591 | Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series |
| Q26749576 | Immunological markers of rheumatoid arthritis |
| Q37321691 | Inclusion body myositis associated with Sjögren's syndrome |
| Q52861667 | Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment. |
| Q49693642 | Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis |
| Q58779775 | Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management |
| Q64240249 | Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial |
| Q35605418 | MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial |
| Q38072667 | Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation |
| Q55044448 | Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice. |
| Q53098766 | Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. |
| Q42747762 | Nodular changes in lungs in a patient with rheumatoid arthritis. Diagnostic and therapeutic difficulties. Case report |
| Q114902721 | P35-F Brainstem auditory evoked potentials in patients with primary Sjögren’s syndrome |
| Q37737654 | Palpable mass of the neck in the course of Takayasu arteritis |
| Q92966495 | Panta rhei in diagnosing rheumatic diseases |
| Q55020926 | Parameters of Somatosensory Evoked Potentials in Patients with Primary Sjӧgren's Syndrome: Preliminary Results. |
| Q102331038 | Pathophysiology of hyperuricemia and its clinical significance - a narrative review |
| Q37522254 | Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement |
| Q53037368 | Peripheral blood Th17/Treg imbalance in patients with low-active systemic lupus erythematosus. |
| Q41182024 | Polymorphisms within Genes Involved in Regulation of the NF-κB Pathway in Patients with Rheumatoid Arthritis. |
| Q35829089 | Pregnancy exacerbates complications of acquired hemophilia in a patient with systemic lupus erythematosus |
| Q64996337 | Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. |
| Q89485810 | Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sjögren's syndrome |
| Q44532248 | Proximal tubule damage in patients treated with gentamicin or amikacin |
| Q51838009 | Rapid and complete resolution of ascites and hydrothorax due to nephrotic syndrome caused by renal amyloidosis in a patient with juvenile chronic arthritis treated with adalimumab. |
| Q64039957 | Relapsing polychondritis - analysis of symptoms and criteria |
| Q26773824 | Reported concepts for the treatment modalities and pain management of temporomandibular disorders |
| Q33720765 | Results from Polish Spondyloarthritis Initiative registry (PolSPI) - methodology and data from - the first year of observation |
| Q90453870 | Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study |
| Q55046518 | Septic arthritis of the sacroiliac joint. |
| Q86123939 | Significance of association of HLA-C and HLA-E with psoriatic arthritis |
| Q101062996 | Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study |
| Q91400802 | Systemic Lupus Erythematosus Induced by Autoimmune/ Inflammatory Syndrome Induced by Adjuvants. Is it Possible? Long-Term Follow-up and Literature Review |
| Q35656933 | Temporomandibular disorders and oral parafunctions: mechanism, diagnostics, and therapy |
| Q38821111 | The Activity of JAK/STAT and NF-κB in Patients with Rheumatoid Arthritis. |
| Q38391791 | The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis |
| Q40540138 | The Safety of Intravenous Cyclophosphamide in the Treatment of Rheumatic Diseases |
| Q92501749 | The effect of LILRB1 but not LILRA3 gene polymorphism in immunopathology of ankylosing spondylitis-A parallel to KIR genes |
| Q42143945 | The pathogenesis of rheumatoid arthritis in radiological studies. Part I: Formation of inflammatory infiltrates within the synovial membrane and I. Sudoł-Szopińska, K. Zaniewicz-Kaniewska, A. Warczyńska, G. Matuszewska, F. Saied, W. Kunisz The patho |
| Q49215788 | The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis |
| Q46346274 | The role of microRNA-5196 in the pathogenesis of systemic sclerosis. |
| Q49289889 | The variety of clinical presentations in IgG4-related disease in Rheumatology |
| Q90243664 | Tofacitinib in the treatment of active rheumatoid arthritis - single-centre experience |
| Q58779800 | Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology |
| Q83684319 | [A case of early recognized Wegener's granulomatosis with renal involvement. Insights for early diagnosis] |
| Q75186755 | [Amyloidosis in the course of rheumatic disease: pathogenesis, incidence, clinical aspects and diagnosis] |
| Q73237050 | [Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumat |
| Q95351609 | [Bilateral exophthalmos requiring rheumatologic consultation. A case of the Churg-Strauss syndrome] |
| Q95525486 | [Coexistence of systemic sclerosis and gout? Hyperuricemia in systemic sclerosis: case report and literature review] |
| Q50465505 | [Enhanced ocular staining score in patients with primary Sjögren's syndrome]. |
| Q95479508 | [Eosinophilic fasciitis--a case report] |
| Q54437884 | [Musculoskeletal symptoms in systemic lupus erythematosus and their differential diagnosis with rheumatoid arthritis]. |
| Q75186777 | [Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose of methotrexate] |
| Q84513338 | [The role of Th1, Th17, and Treg cells in the pathogenesis of rheumatoid arthritis including anti-inflammatory action of Th1 cytokines] |
| Q83989997 | [Toxic epidermal necrolysis during therapy with sulphasalazine in a patient with arthritis. Case report] |
| Q75186758 | [Treatment and prognosis of secondary amyloidosis in the course of rheumatic disease] |
| Q81135568 | [Treatment outcome of spondyloarthropathy with infliximab] |
Search more.